AAD
Author: Willhemenia Loremipsum Special session: Lorem ipsum dolor sit amet Category: Lorem ipsum View all results

Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

Socially-Driven Disparities in Acral Melanoma

Description

The presentation discusses disparities in acral melanoma, emphasizing that these inequalities are influenced by social factors. A case study of a 73-year-old Spanish-speaking woman highlights delays in her diagnosis and treatment due to communication barriers, cultural perceptions, and access to care. Despite increasing melanoma survival rates, inequities persist, particularly affecting Hispanic and non-Hispanic Black populations, often resulting in late-stage diagnoses. Key contributors to these disparities include lack of insurance, language barriers, and inadequate public education about melanoma risks in diverse populations. The speaker calls for culturally relevant education, improved access to health care, and more inclusive clinical trials to address these disparities, advocating for a multidisciplinary approach to treatment until better therapies are available. The necessity of targeted outreach and the involvement of multiple specialties in patient care is underscored to improve outcomes for at-risk populations.

View more

Conclusions

  • Socially driven disparities significantly affect individuals with acral melanoma, leading to delayed diagnosis and treatment.
  • Cultural and language barriers, such as the need for interpreters, are independently associated with late-stage melanoma presentations.
  • The perception that melanoma primarily affects lighter-skinned individuals contributes to a lack of awareness and delayed care among people of color.
  • Interventions should focus on improving patient education regarding melanoma risks, specifically in communities of color.
  • Access to care is critical; individuals entering the emergency department face the highest risks of late-stage diagnosis when needing interpreter services.
  • Social determinants like insurance status, language, and point of entry into the healthcare system play significant roles in health outcomes for melanoma patients.
  • Lack of representation in clinical trials hinders the generalizability of findings and access to advancements in melanoma treatment for underrepresented populations.
  • A multidisciplinary approach is necessary to address treatment decisions and support for patients from diverse backgrounds, especially regarding fears of amputation.
  • Timely intervention can significantly improve melanoma survival rates, yet disparities in access to specialists persist.
  • Huff LS, Chang CA, Thomas JF, et al. Defining an acceptable period of time from melanoma biopsy to excision. Dermatol Reports. 2012;4(1):e2.
  • Qian et al. The ongoing racial disparities in melanoma: An analysis of the Surveillance, Epidemiology, and End Results database (1975-2016). J Am Acad Dermatol. 2021;84(6):1585-1593.
  • Fernandez et al. Survival of Hispanic Patients with Cutaneous Melanoma: A Retrospective Cohort Analysis of 6,016 Cases from the National Cancer Database [published online ahead of print, 2022 Oct 10]. J Am Acad Dermatol. 2022;S0190-9622(22)02806-7.
  • Robinson JK, Joshi KM, Ortiz S, Kundu RV. Melanoma knowledge, perception, and awareness in ethnic minorities in Chicago: recommendations regarding education. Psychooncology. 2011;20(3):313-320.
  • Lopes FCPS, Sleiman MG, Sebastian K, Bogucka R, Jacobs EA, Adamson AS. UV Exposure and the Risk of Cutaneous Melanoma in Skin of Color: A Systematic Review. JAMA Dermatol. 2021;157(2):213-219.
  • Dubocq-Ortiz C, Encarnacion-Cortes V, Gill JG, Vasquez R. Acral melanoma in a United States safety net hospital: retrospective cohort study. Arch Dermatol Res. 2024;317(1):98.
  • Pagani K, Lukac D, Olbricht SM, et al. Urgent referrals from primary care to dermatology for lesions suspicious for skin cancer: patterns, outcomes, and need for systems improvement. Arch Dermatol Res. 2023;315(5):1397-1400.
  • Ramirez F, Vasquez R, Gill J, et al. Understanding the Association Between Social Determinants of Health and Receipt of Immunotherapy for Melanoma. J Drugs Dermatol. 2024;23(5):311-315.